Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Frederic Tort is active.

Publication


Featured researches published by Frederic Tort.


Nature | 2005

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

Jirina Bartkova; Zuzana Ho rcaron; ejší; Karen Koed; Alwin Krämer; Frederic Tort; Karsten Zieger; Per Guldberg; Maxwell Sehested; Jahn M. Nesland; Claudia Lukas; T F Ørntoft; Jiri Lukas; Jiri Bartek

During the evolution of cancer, the incipient tumour experiences ‘oncogenic stress’, which evokes a counter-response to eliminate such hazardous cells. However, the nature of this stress remains elusive, as does the inducible anti-cancer barrier that elicits growth arrest or cell death. Here we show that in clinical specimens from different stages of human tumours of the urinary bladder, breast, lung and colon, the early precursor lesions (but not normal tissues) commonly express markers of an activated DNA damage response. These include phosphorylated kinases ATM and Chk2, and phosphorylated histone H2AX and p53. Similar checkpoint responses were induced in cultured cells upon expression of different oncogenes that deregulate DNA replication. Together with genetic analyses, including a genome-wide assessment of allelic imbalances, our data indicate that early in tumorigenesis (before genomic instability and malignant conversion), human cells activate an ATR/ATM-regulated DNA damage response network that delays or prevents cancer. Mutations compromising this checkpoint, including defects in the ATM–Chk2–p53 pathway, might allow cell proliferation, survival, increased genomic instability and tumour progression.


Nature | 2006

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints.

Jirina Bartkova; Nousin Rezaei; Michalis Liontos; Panagiotis Karakaidos; Dimitris Kletsas; Natalia Issaeva; Leandros-Vassilios F. Vassiliou; Evangelos Kolettas; Katerina Niforou; Vassilis C. Zoumpourlis; Munenori Takaoka; Hiroshi Nakagawa; Frederic Tort; Kasper Fugger; Fredrik Johansson; Maxwell Sehested; Claus L. Andersen; Lars Dyrskjøt; Torben F. Ørntoft; Jiri Lukas; Christos Kittas; Thomas Helleday; Thanos D. Halazonetis; Jiri Bartek; Vassilis G. Gorgoulis

Recent studies have indicated the existence of tumorigenesis barriers that slow or inhibit the progression of preneoplastic lesions to neoplasia. One such barrier involves DNA replication stress, which leads to activation of the DNA damage checkpoint and thereby to apoptosis or cell cycle arrest, whereas a second barrier is mediated by oncogene-induced senescence. The relationship between these two barriers, if any, has not been elucidated. Here we show that oncogene-induced senescence is associated with signs of DNA replication stress, including prematurely terminated DNA replication forks and DNA double-strand breaks. Inhibiting the DNA double-strand break response kinase ataxia telangiectasia mutated (ATM) suppressed the induction of senescence and in a mouse model led to increased tumour size and invasiveness. Analysis of human precancerous lesions further indicated that DNA damage and senescence markers cosegregate closely. Thus, senescence in human preneoplastic lesions is a manifestation of oncogene-induced DNA replication stress and, together with apoptosis, provides a barrier to malignant progression.


Laboratory Investigation | 2001

Molecular Characterization of a New ALK Translocation Involving Moesin (MSN-ALK) in Anaplastic Large Cell Lymphoma

Frederic Tort; Magda Pinyol; Karen Pulford; Giovanna Roncador; Lluis Hernández; Iracema Nayach; Hanneke C. Kluin-Nelemans; Philip M. Kluin; Christian Touriol; Georges Delsol; David Y. Mason; Elias Campo

The majority of anaplastic large cell lymphomas (ALCL) are associated with chromosomal abnormalities affecting the anaplastic lymphoma kinase (ALK) gene which result in the expression of hybrid ALK fusion proteins in the tumor cells. In most of these tumors, the hybrid gene comprises the 5′ region of nucleophosmin (NPM) fused in frame to the 3′ portion of ALK, resulting in the expression of the chimeric oncogenic tyrosine kinase NPM-ALK. However, other variant rearrangements have been described in which ALK fuses to a partner other than NPM. Here we have identified the moesin (MSN) gene at Xq11–12 as a new partner of ALK in a case of ALCL which exhibited a distinctive membrane-restricted pattern of ALK labeling. The hybrid MSN-ALK protein had a molecular weight of 125 kd and contained an active tyrosine kinase domain. The unique membrane staining pattern of ALK is presumed to reflect association of moesin with cell membrane proteins. In contrast to other translocations involving the ALK gene, the ALK breakpoint in this case occurred within the exonic sequence coding for the juxtamembrane portion of ALK. Identification of the genomic breakpoint confirmed the in-frame fusion of the whole MSN intron 10 to a 17 bp shorter juxtamembrane exon of ALK. The breakpoint in der(2) chromosome showed a deletion, including 30 bp of ALK and 36 bp of MSN genes. These findings indicate that MSN may act as an alternative fusion partner for activation of ALK in ALCL and provide further evidence that oncogenic activation of ALK may occur at different intracellular locations.


The Journal of Pathology | 2005

Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms

Joaquim Carreras; Neus Villamor; Lluis Colomo; Carol Moreno; Santiago Ramón y Cajal; Marta Crespo; Frederic Tort; Francesc Bosch; Armando López-Guillermo; Dolors Colomer; Emili Montserrat; Elias Campo

ZAP‐70 is a tyrosine kinase that participates in early B‐cell differentiation and is a prognostic factor in chronic lymphocytic leukaemia (CLL), where it is associated with an unmutated configuration of the IgVH genes. In this study ZAP‐70 expression was studied by immunohistochemistry in a spectrum of B‐cell lymphoid neoplasms; this staining method was compared with flow cytometry, and the relationship of ZAP‐70 expression to mutational status and prognosis was assessed. 242 tissue samples from 225 patients with B‐cell lymphoid neoplasms arising at different maturational stages were included. Flow cytometry was performed in all CLL cases (n = 52). IgVH mutational status was determined in 25 CLL and 12 mantle cell lymphoma (MCL) patients. ZAP‐70 was positive in 34/52 (65%) CLL, 9/31 (31%) Burkitts lymphoma, 2/7 (29%) lymphoblastic lymphomas, 3/36 (8%) MCL, 1/23 (4%) marginal zone lymphoma, and 1/45 (2%) diffuse large B‐cell lymphomas, but in none of the 19 follicular lymphomas or the 14 Hodgkin lymphomas. An identical ZAP‐70 pattern was obtained in six patients with simultaneous biopsies from different sites and in 12 patients with sequential biopsies. Immunohistochemistry and flow cytometry gave identical results in 48 the 52 CLLs. All but one ZAP‐70‐positive CLL had IgVH gene in an unmutated configuration, whereas all but one ZAP‐70‐negative CLL had somatically hypermutated IgVH. The 12 MCLs analysed were ZAP‐70 negative regardless of IgVH mutational status (4 mutated, 8 unmutated). ZAP‐70 positive CLL was associated with a shorter overall survival (median time 103 months vs. 293 months, p = 0.01) and a shorter time to disease progression (median time 26 months vs. 60 months, p = 0.01). In conclusion, ZAP‐70 is expressed in several types of B‐cell neoplasm and is easily detected by immunohistochemistry, providing a useful prognostic marker in patients with CLL from whom no other material is available or when other techniques for its assessment cannot be performed. Copyright


Leukemia | 2005

Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms

Frederic Tort; Silvia Hernández; Sílvia Beà; Emma Camacho; Verònica Fernàndez; Manel Esteller; Mario F. Fraga; Christof Burek; Andreas Rosenwald; Lluis Hernández; Elias Campo

CHK1 gene encodes for a serine/threonine kinase involved in the regulation of cell cycle progression and DNA damage checkpoints. To determine the role of CHK1 in the pathogenesis of lymphoid neoplasms and its relationship to other DNA damage response genes, we have analyzed the gene status, protein, and mRNA expression in a series of tumors and nonneoplastic lymphoid tissues. CHK1 protein and mRNA expression levels were very low in both reactive tissues and resting lymphoid cells, whereas tumor samples showed a variable pattern of expression related to their proliferative activity. However, seven aggressive tumors showed a dissociate pattern of extremely low or negative protein expression in spite of a high proliferative activity. Four of these tumors were diffuse large B-cell lymphomas (DLCLs) with concordant reduced levels of mRNA, whereas one blastoid mantle cell lymphoma (B-MCL) and two DLCLs had relatively normal levels of mRNA. No gene mutations, deletions, or hypermethylation of the promoter region were detected in any of these cases. In all these tumors ATM, CHK2, and p53 genes were wild type. These findings suggest that CHK1 inactivation in NHLs occurs by loss of protein expression in a subset of aggressive variants alternatively to ATM, CHK2, and p53 alterations.


Cancer Research | 2001

BMI-1 Gene Amplification and Overexpression in Hematological Malignancies Occur Mainly in Mantle Cell Lymphomas

Sílvia Beà; Frederic Tort; Magda Pinyol; Xavier Puig; Luis Hernández; Silvia Hernández; Pedro L. Fernández; Maarten van Lohuizen; Dolors Colomer; Elias Campo


Archive | 2006

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage

Jirina Bartkova; Nousin Rezaei; Michalis Liontos; Panagiotis Karakaidos; Dimitris Kletsas; Natalia Issaeva; Leandros-Vassilios F. Vassiliou; Evangelos Kolettas; Katerina Niforou; Vassilis Zoumpourlis; Munenori Takaoka; Hiroshi Nakagawa; Frederic Tort; Kasper Fugger; Fredrik Johansson; Maxwell Sehested; Claus L. Andersen; Lars Dyrskjøt; Torben F. Ørntoft; Jiri Lukas; Christos Kittas; Thomas Helleday; Thanos D. Halazonetis; Jiri Bartek; Vassilis G. Gorgoulis


Blood | 2002

CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas

Frederic Tort; Silvia Hernández; Sílvia Beà; Antonio Martinez; Manel Esteller; James G. Herman; Xavier Puig; Emma Camacho; Montse Sánchez; Iracema Nayach; Armando López-Guillermo; Pedro L. Fernández; Dolors Colomer; Luis Hernández; Elias Campo


Cancer Research | 2006

Retinoblastoma Pathway Defects Show Differential Ability to Activate the Constitutive DNA Damage Response in Human Tumorigenesis

Frederic Tort; Jirina Bartkova; Maxwell Sehested; Torben F. Ørntoft; Jiri Lukas; Jiri Bartek


Human Pathology | 2004

Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma

Frederic Tort; Elias Campo; Brad Pohlman; Eric D. Hsi

Collaboration


Dive into the Frederic Tort's collaboration.

Top Co-Authors

Avatar

Elias Campo

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sílvia Beà

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Emma Camacho

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar

Jiri Lukas

University of Copenhagen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Francesc Bosch

Autonomous University of Barcelona

View shared research outputs
Researchain Logo
Decentralizing Knowledge